## **Conrad Muzoora**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6160012/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. New England Journal of Medicine, 2014, 370, 2487-2498.	13.9	387
2	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clinical Infectious Diseases, 2014, 58, 736-745.	2.9	299
3	Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Social Science and Medicine, 2012, 74, 2012-2019.	1.8	253
4	Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast. Emerging Infectious Diseases, 2014, 20, 45-53.	2.0	253
5	Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 68-75.	4.6	240
6	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIVâ€Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. Clinical Infectious Diseases, 2009, 49, 702-709.	2.9	201
7	Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Aids, 2011, 25, 2123-2131.	1.0	195
8	Dose Response Effect of Highâ€Dose Fluconazole for HIVâ€Associated Cryptococcal Meningitis in Southwestern Uganda. Clinical Infectious Diseases, 2008, 47, 1556-1561.	2.9	180
9	The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 1607-1614.	2.9	145
10	Internalized Stigma, Social Distance, and Disclosure of HIV Seropositivity in Rural Uganda. Annals of Behavioral Medicine, 2013, 46, 285-294.	1.7	129
11	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	13.9	119
12	Point-of-Care Diagnosis and Prognostication of Cryptococcal Meningitis With the Cryptococcal Antigen Lateral Flow Assay on Cerebrospinal Fluid. Clinical Infectious Diseases, 2014, 58, 113-116.	2.9	107
13	The Dynamic Relationship Between Social Support and HIV-Related Stigma in Rural Uganda. Annals of Behavioral Medicine, 2014, 48, 26-37.	1.7	104
14	The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 210, 383-391.	1.9	101
15	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2015, 59, 7224-7231.	1.4	99
16	Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infectious Diseases, The, 2019, 19, 843-851.	4.6	92
17	GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. Aids, 2013, 27, 1503-1508.	1.0	83
18	Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Diseases, The, 2020, 20, 308-317.	4.6	80

#	Article	IF	CITATIONS
19	How Does Antiretroviral Treatment Attenuate the Stigma of HIV? Evidence from a Cohort Study in Rural Uganda. AIDS and Behavior, 2013, 17, 2725-2731.	1.4	75
20	Reversal of the Kynurenine Pathway of Tryptophan Catabolism May Improve Depression in ART-Treated HIV-Infected Ugandans. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 456-462.	0.9	72
21	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. Journal of Infection, 2012, 64, 76-81.	1.7	69
22	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	0.9	68
23	High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda. AIDS Patient Care and STDs, 2016, 30, 4-10.	1.1	67
24	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	4.6	63
25	Realtime adherence monitoring of antiretroviral therapy among hiv-infected adults and children in rural uganda. Aids, 2013, 27, 2166-2168.	1.0	62
26	Evidence for the Reliability and Validity of the Internalized AIDS-Related Stigma Scale in Rural Uganda. AIDS and Behavior, 2013, 17, 427-433.	1.4	59
27	Is Sub-Saharan Africa prepared for COVID-19?. Tropical Medicine and Health, 2020, 48, 18.	1.0	51
28	Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive Women Initiating Antiretroviral Therapy in Mbarara, Uganda. PLoS ONE, 2013, 8, e63411.	1.1	51
29	Digital monitoring technologies could enhance tuberculosis medication adherence in Uganda: Mixed methods study. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 17, 100119.	0.6	49
30	Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation. Open Forum Infectious Diseases, 2018, 5, ofy122.	0.4	44
31	Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 317-321.	0.9	43
32	The Mouse Inhalation Model of <i>Cryptococcus neoformans</i> Infection Recapitulates Strain Virulence in Humans and Shows that Closely Related Strains Can Possess Differential Virulence. Infection and Immunity, 2019, 87, .	1.0	43
33	HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. Journal of Infectious Diseases, 2019, 219, 877-883.	1.9	43
34	Rethinking the "Pre―in Pre-Therapy Counseling: No Benefit of Additional Visits Prior to Therapy on Adherence or Viremia in Ugandans Initiating ARVs. PLoS ONE, 2012, 7, e39894.	1.1	42
35	AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials, 2018, 19, 649.	0.7	41
36	High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases, 2021, 73, 876-884.	2.9	40

#	Article	IF	CITATIONS
37	The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015–2017. Open Forum Infectious Diseases, 2019, 6, ofz419.	0.4	38
38	Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis. Clinical Infectious Diseases, 2019, 68, 2094-2098.	2.9	33
39	Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. Aids, 2017, 31, 169-171.	1.0	31
40	Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1581-1584.	1.3	28
41	Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. New England Journal of Medicine, 2020, 382, 2397-2410.	13.9	27
42	The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. Genes and Immunity, 2012, 13, 83-93.	2.2	26
43	Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda. AIDS Research and Human Retroviruses, 2014, 30, 896-906.	0.5	26
44	Point-of-Care C-Reactive Protein Testing to Facilitate Implementation of Isoniazid Preventive Therapy for People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 551-556.	0.9	25
45	Optimizing Network Connectivity for Mobile Health Technologies in sub-Saharan Africa. PLoS ONE, 2012, 7, e45643.	1.1	25
46	Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis. HIV Medicine, 2017, 18, 13-20.	1.0	24
47	Dissemination of Research Findings to Research Participants Living with HIV in Rural Uganda: Challenges and Rewards. PLoS Medicine, 2013, 10, e1001397.	3.9	23
48	HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods. Aids, 2013, 27, S105-S112.	1.0	23
49	Bedside measures of malnutrition and association with mortality in hospitalized adults. Clinical Nutrition, 2015, 34, 252-256.	2.3	23
50	Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. Aids, 2017, 31, 2345-2354.	1.0	23
51	Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2015, 2, ofv157.	0.4	22
52	Evaluation of a point-of-care immunoassay test kit â€~StrongStep' for cryptococcal antigen detection. PLoS ONE, 2018, 13, e0190652.	1.1	22
53	Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. Open Forum Infectious Diseases, 2020, 7, ofaa100.	0.4	21
54	Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis. Journal of Infectious Diseases, 2017, 215, 693-697.	1.9	20

#	Article	IF	CITATIONS
55	Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa. Clinical Infectious Diseases, 2020, 71, 525-531.	2.9	20
56	Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda. Wellcome Open Research, 2018, 3, 64.	0.9	20
57	Upper gastrointestinal diseases in patients for endoscopy in South-Western Uganda. African Health Sciences, 2015, 15, 959.	0.3	19
58	Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding. Open Forum Infectious Diseases, 2016, 3, ofv194.	0.4	18
59	Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality. PLoS ONE, 2018, 13, e0209337.	1.1	18
60	Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda. Annals of Internal Medicine, 2018, 169, 146.	2.0	18
61	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. Journal of Virology, 2019, 93, .	1.5	17
62	Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. Clinical Infectious Diseases, 2020, 71, e45-e49.	2.9	17
63	Disinhibition in Risky Sexual Behavior in Men, but Not Women, during Four Years of Antiretroviral Therapy in Rural, Southwestern Uganda. PLoS ONE, 2013, 8, e69634.	1.1	16
64	Treatment as long-term prevention. Aids, 2014, 28, 267-271.	1.0	16
65	Tobacco Use Among Adults Initiating Treatment for HIV Infection in Rural Uganda. AIDS and Behavior, 2014, 18, 1381-1389.	1.4	15
66	Evaluation of the BioFire® FilmArray® Meningitis/Encephalitis panel in an adult and pediatric Ugandan population. Journal De Mycologie Medicale, 2021, 31, 101170.	0.7	15
67	Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes. Open Forum Infectious Diseases, 2019, 6, ofz478.	0.4	15
68	Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006–2016. Open Forum Infectious Diseases, 2017, 4, ofx077.	0.4	14
69	Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 386-391.	0.9	14
70	Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005–2013. AIDS Patient Care and STDs, 2018, 32, 257-264.	1.1	13
71	No Association Found Between Traditional Healer Use and Delayed Antiretroviral Initiation in Rural Uganda. AIDS and Behavior, 2013, 17, 260-265.	1.4	12
72	Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara Regional Referral Hospital, southwestern Uganda. Journal of Blood Medicine, 2018, Volume 9, 105-110.	0.7	12

#	Article	IF	CITATIONS
73	Tuberculosis in HIV-Associated Cryptococcal Meningitis is Associated with an Increased Risk of Death. Journal of Clinical Medicine, 2020, 9, 781.	1.0	12
74	Super learner analysis of realâ€time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to nonâ€differentiated care approaches for persons living with HIV in rural Uganda. Journal of the International AIDS Society, 2020, 23, e25467.	1.2	12
75	Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis. Clinical Infectious Diseases, 2021, 73, e3077-e3082.	2.9	11
76	Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. Medical Mycology, 2020, 58, 282-292.	0.3	10
77	Handheld Point-of-Care Cerebrospinal Fluid Lactate Testing Predicts Bacterial Meningitis in Uganda. American Journal of Tropical Medicine and Hygiene, 2013, 88, 127-131.	0.6	9
78	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. Aids, 2020, 34, 1425-1428.	1.0	9
79	Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness. Antibiotics, 2021, 10, 739.	1.5	9
80	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. Clinical Infectious Diseases, 2010, 51, 986-987.	2.9	7
81	Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. Aids, 2021, 35, 1083-1089.	1.0	7
82	<i>CYP2B6</i> Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Research and Human Retroviruses, 2018, 34, 982-992.	0.5	6
83	AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. BMJ Open, 2019, 9, e026288.	0.8	6
84	Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. Journal of Virology, 2020, 94, .	1.5	6
85	Correlation between Blood and CSF Compartment Cytokines and Chemokines in Subjects with Cryptococcal Meningitis. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	5
86	Incidence and predictors of early loss to follow up among patients initiated on protease inhibitor-based second-line antiretroviral therapy in southwestern Uganda. AIDS Research and Therapy, 2021, 18, 7.	0.7	5
87	Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research, 0, 3, 64.	0.9	5
88	Internalized stigma, depressive symptoms, and the modifying role of antiretroviral therapy: A cohort study in rural Uganda. SSM Mental Health, 2021, 1, 100034.	0.9	5
89	Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, ofx127.	0.4	4
90	Positive Deviance for Dual-Method Promotion among Women in Uganda: A Qualitative Study. International Journal of Environmental Research and Public Health, 2020, 17, 5009.	1.2	4

#	Article	IF	CITATIONS
91	Association Between Immunoglobulin E Levels and Kaposi Sarcoma in African Adults With Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2021, 223, 101-108.	1.9	4
92	Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting. Research Involvement and Engagement, 2020, 6, 49.	1.1	3
93	Positive deviance for dual-method promotion among women in Uganda: study protocol for a cluster randomized controlled trial. Trials, 2020, 21, 270.	0.7	3
94	The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis. Wellcome Open Research, 0, 6, 45.	0.9	3
95	Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. Medical Mycology, 2021, 59, 712-719.	0.3	3
96	Diagnostic and Prognostic Value of Cerebrospinal Fluid Lactate and Glucose in HIV-Associated Tuberculosis Meningitis. Microbiology Spectrum, 0, , .	1.2	3
97	Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. Aids, 2016, 30, 1781-1788.	1.0	2
98	Positive deviance for promoting dual-method contraceptive use among women in Uganda: a cluster randomised controlled trial. BMJ Open, 2021, 11, e046536.	0.8	2
99	Predictors of Medication-Related Emergency Department Admissions Among Patients with Cardiovascular Diseases at Mbarara Regional Referral Hospital, South-Western Uganda. Open Access Emergency Medicine, 2021, Volume 13, 279-290.	0.6	1
100	Knowledge, attitude, and preferred strategies towards HIV/AIDS prevention among adolescents attending secondary schools in South Western Uganda. African Health Sciences, 2021, 21, 1067-1073.	0.3	1
101	A Journey of Hope: giving research participants a voice to share theirÂexperiences and improve community engagement aroundÂadvanced HIV disease in Uganda. AAS Open Research, 2020, 3, 33.	1.5	1
102	A Journey of Hope: giving research participants a voice to share theirÂexperiences and improve community engagement aroundÂadvanced HIV disease in Uganda. AAS Open Research, 0, 3, 33.	1.5	1
103	Early empiric anti- <i>Mycobacterium tuberculosis</i> therapy for sepsis in sub-Saharan Africa: a protocol of a randomised clinical trial. BMJ Open, 2022, 12, e061953.	0.8	1
104	Subtype-Specific HIV-1 Adaptation to Host HLA. AIDS Research and Human Retroviruses, 2014, 30, A218-A218.	0.5	0
105	Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors. Frontiers in Virology, 0, 2, .	0.7	0